TCEANC2

Across TCGA pan-cancer cohorts, TCEANC2 mass-spec protein differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of TCEANC2’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where TCEANC2 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types TCEANC2 is over-expressed in tumor, although a few such as PDAC show the opposite, repressed pattern.

HNSC, PDAC, and LSCC are the cancer types where TCEANC2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TCEANC2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	All	II,III,IV	+0.276	.019	4	view →
PDAC	Male	All	−0.825	.015	2	view →
LSCC	Female	II,III,IV	+0.466	.040	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

TCEANC2–HNSC

Open the HNSC breakdown →